Showing results (11-20 of 443) with videos related to
Sort By:
Pageof 45
Clinical Genitourinary Cancer|February 14, 2009
Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinomaKathryn A Bylow, Michael B Atkins, Edwin M Posadas, et al.HPB : the Official Journal of the International Hepato Pancreato Biliary Association|July 11, 2009
Refining indications for contemporary surgical treatment of renal cell carcinoma metastatic to the pancreasAram N Demirjian, Charles M Vollmer, David F McDermott, et al.Immunotherapy|March 12, 2019
Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparisonMichael B Atkins, Ahmad Tarhini, Michael Rael, et al.Immunotherapy|January 30, 2020
Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinomaApoorva Ambavane, Shuo Yang, Michael B Atkins, et al.Cancer|March 28, 2006
Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacyKen Wyman, Michael B Atkins, Victor Prieto, et al.Melanoma Research|December 2, 2021
Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitorsCharlene M Mantia, Lillian Werner, Brian Stwalley, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 11, 2002
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanomaMichael B Atkins, Jared A Gollob, Jeffrey A Sosman, et al.Journal for Immunotherapy of Cancer|January 30, 2026
Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinomaHollis Viray, Charlene M Mantia, Opeyemi A Jegede, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leakDiana C Gallagher, Rupal S Bhatt, Samir M Parikh, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Cytokine-based therapy and biochemotherapy for advanced melanomaMichael B AtkinsPageof 45